Premium
Sustained renal function loss in psoriasis patients after withdrawal of low‐dose cyclosporin therapy
Author(s) -
KORSTANJE M.J.,
BILO H.J.G.,
STOOF T.J.
Publication year - 1992
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1992.tb14848.x
Subject(s) - effective renal plasma flow , renal function , urology , medicine , psoriasis , renal blood flow , endocrinology , dermatology
Summary Eight patients with psoriasis received low‐dose cyclosporin (CyA) treatment for an average period of 12 months (range 4–16 months). There was great variability in minimal effective CyA dose. In 50% of the patients long‐term treatment was limited by dose reductions necessitated by side‐effects. A considerable impairment of renal function during CyA therapy was found. Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured with 125 I‐iothalamate and 131 Ibippuran, respectively. Both at the end of the active treatment period (GFR‐CyA and ERPF‐CyA), and 4 months after withdrawal of CyA (GFR‐4mo and ERPF‐4mo), there was sustained renal impairment: GFR‐BL = 97 (64–117), GFR‐CyA reduction 17·8% (2·2–31·9%) P < 0·02], GFR‐4mo reduction = 9·8% (5·5–21·5%) ml/min/1·73 m 2 (P < 0·05 vs. BL); ERPF‐BL = 401 (232–607), ERPF‐CyA reduction =10·1% (7·4–27·3%) [P < 0·05], ERPF‐4mo reduction=13·5% (3·0–32·9%) ml/min/1·73 m 2 (P < 0·02). Further studies of the effects on renal function during, and after, long‐term therapy of psoriasis with low‐dose CyA are warranted.